-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
Jounce Therapeutics, Inc. quarterly/annual Earnings Per Share, Diluted history and growth rate from 2018 to 2022.
- Jounce Therapeutics, Inc. Earnings Per Share, Diluted for the quarter ending December 31, 2022 was 0.98 USD/shares.
- Jounce Therapeutics, Inc. Earnings Per Share, Diluted for the twelve months ending December 31, 2022 was -0.99 USD/shares, a 45.6% increase year-over-year.
- Jounce Therapeutics, Inc. annual Earnings Per Share, Diluted for 2022 was -0.99 USD/shares, a 45.6% increase from 2021.
- Jounce Therapeutics, Inc. annual Earnings Per Share, Diluted for 2021 was -1.82 USD/shares, a 46.8% decline from 2020.
- Jounce Therapeutics, Inc. annual Earnings Per Share, Diluted for 2020 was -1.24 USD/shares, a 175% decline from 2019.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Annual (USD/shares)
Earnings Per Share, Diluted, YoY Annual Growth (%)